• (PLX AI) – Oncopeptides withdraws Pepaxto in US; to scale down organization and focus on R&D.
  • • Oncopeptides says U.S. FDA does not consider that the phase 3 OCEAN study meets the criteria of a confirmatory study
  • • OCEAN data didn't pass the regulatory hurdles to confirm the accelerated approval in the US, the company said
  • • Company postpones earnings report to Nov. 24
  • • Shares down 43%

Quelle: PLX AI